Telix Pharmaceuticals Limited (ASX: TLX) operates in the healthcare sector and is engaged in commercialisation and development of molecularly targeted radiation (MTR) products for the treatment of cancer. The company is based out of North Melbourne, Australia.
Telix’s Clinical Pipeline (Image source: Company’s report)
TLX has recently inked a deal with the Emory Winship Cancer Institute for a Clinical Trial using Advanced Imaging of Prostate Cancer for Radiotherapy. Ashesh Jani (Winship Radiation Oncologist) and David Schuster (Emory Radiologist and Nuclear Medicine Physician) will be leading the trial. The trial involves numerous ingenious purposes such as the first use of PSMA PET in Georgia. With the said study, the Emory University continues its tradition of innovation and development.
Insights into the deal
A grant amounting to US$3.4 million by the National Institutes of Health has been offered to the researchers at the Winship Cancer Institute, Emory University in Atlanta, USA. The underlying purpose is to compare Axumin® against Ga-PSMA in high-risk prostate cancer patients that will be receiving radiation therapy following prostatectomy. Telix will provide the PSMA PET imaging for the study and act as a Technology Partner and Collaborator for the grant. The study will be conducted on a population of 140 patients.
As per a prior comparative experience between PSMA imaging and Axumin®, PSMA imaging came out to be superior in terms of detection. Axumin® was developed by Emory University and is approved for metastatic prostate cancer currently in the US.
The study is aimed at identifying any advanced prostate imaging techniques to guide radiotherapy. The research will help evaluate prostate imaging’s potential to impact the implementation of radiotherapy techniques.
Also, Telix is selected as a part of the study on account of the ongoing collaborative clinical study of Ga-PSMA imaging’s future implications. The company has provided easy to use products that have made nuclear pharmacy validation straightforward. The collaboration with Emory Winship Cancer Institute is expected to be a great step forward in the domain.
Steps towards the development of illumet™
Recently, Telix has also made progress with the development of illumet™. It has put forward a pre-New Drug Application meeting request to the US Food and Drug Administration. The purpose is to obtain a marketing authorisation for the illumet™ prostate cancer imaging product in the United States.
The meeting with the FDA is expected to take place in the month of July, and the company has prepared a comprehensive pre-NDA package for the same. For the product, Telix also has other distribution partners. It recently executed a distribution agreement with United Pharmacy Partners Inc. The company has also entered into another agreement with PharmaLogic, located in the Northeast and Western United States. The deals mentioned above helped Telix to expand its distribution network and strengthen its presence in the US market. The deals have also provided extended partnering options for the company.
Currently, the stock of the company is trading at a price of $1.055, with a market capitalisation of $216.18 million as on 31st May 2019.